Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses

摘要

The invention relates to antibodies to the tumor-associated antigen CD33 and to the use thereof for immunotargeting CD33-positive cells. The antibodies according to the invention are suitable for use in the field of medicine, pharmaceuticals, and biomedical research. According to the invention, the aim is achieved by means of novel anti-CD33 antibodies comprising the complementary determining regions (CDRs) defined in the claim. The antibodies according to the invention are characterized by a high affinity for human CD33, of the order of magnitude of 10−10 mol/l. The CDR sequences according to the invention are suitable in particular for producing recombinant fragments (such as scFv fragments or bispecific antibodies) and for immunotargeting, due to the high affinity thereof. The invention further relates to the use of an antibody according to the invention for producing a medication for therapeutic and/or diagnostic application for illnesses associated with the expression of CD33, particularly for acute myeloid leukemia (AML). The invention thus also comprises a pharmaceutical composition comprising one or more antibodies according to the invention in association with a pharmaceutically acceptable thinning agent or carrier.

主权项

1. An isolated monoclonal anti-CD33 antibody containing six complementary determining regions (CDRs), characterized in that the six CDRs comprise the following sequences:
a) variable region of heavy chain (VH)
CDR1 DYVVH (SEQ ID No. 1),CDR2 YINPYNDGTKYNEKFKG (SEQ ID No. 2),CDR3 DYRYEVYGMDY (SEQ ID No. 3), and b) variable region of light chain (VL)
CDR1 TASSSVNYIH (SEQ ID No. 4),CDR2 TSKVAS (SEQ ID No. 5),CDR3 QQWRSYPLT (SEQ ID No. 6).